Fidelity® Explores Possible Investment Opportunities Linked To Personalized Medicine Trend

New Digital Thought Leadership Video and “State of the Sector” Paper Highlight Patient-Centric Trend and Health Care Industry Fundamentals

BOSTON -- Genomics and a more patient-centric health care system have the potential to create significant new investment opportunities, according to a new thought leadership initiative by Fidelity Investments®, one of the world’s leading financial services providers with $1.6 trillion in managed assets1.

The emerging trend, called “personalized medicine,” is featured in a new analysis authored by Eddie Yoon, health care equity research analyst and portfolio manager at Fidelity Investments. Yoon also is featured in a new digital video as part of the company’s “Thinking Big” initiative.

“Research today will make it possible for doctors tomorrow to anticipate which treatments will work best for each person, and deliver more effective, less expensive care,” said Yoon. “That means fewer trial-and-error prescriptions and a steep drop in the number of adverse drug reactions, which cause over 770,000 injuries and deaths a year in the United States.2

“On the whole, the health care sector may continue to face secular headwinds in the form of costs and reimbursement pressures, but advancements and trends in personalized medicine provide investing opportunities in companies that are offering innovative products and services that help our health care system better serve patients and save money,” continued Yoon.

Through the new “Thinking Big” video and “State of the Sector” paper, Yoon provides a thought-provoking and informative look at recent developments in personalized medicine, as well as insights into the current fundamentals of the health care sector. For example:

• A key enabler of the personalized medicine trend is the ability to harness DNA data through genetic sequencing. The first human genome was sequenced in 2003 after more than 13 years and at a cost of nearly $3 billion. Today, sequencing a human genome takes less than two weeks and cost as little as a few thousand dollars.3

• With an estimated 90% of prescription drugs working only about 50% of the time, prescribing physicians could use molecular diagnostics to test for specific genetic mutations that might cause one drug to be harmful, while another might be safe.

• The U.S. personalized medicine market is estimated at $232 billion today, and is projected to double to $450 billion by 2015, an increase of 11% per year.4

• A more patient-centric system could save the health care industry billions of dollars a year and help individuals receive more effective care.

• Despite regulatory and austerity headwinds, health care earnings in aggregate were positive for the first three months of 2012 and beat analysts’ estimates for the twelfth consecutive quarter.5

Thinking Big Initiative
Launched in February 2012, the “Thinking Big” initiative has featured thought-provoking topics such as Water Economics and Synthetic Biology. The program builds on Fidelity’s comprehensive thought leadership and investor education efforts, showcasing leading-edge insights generated by the firm’s team of more than 420 equity, fixed income and asset allocation analysts6 across a range of global investment themes.

Whether it’s understanding the economic, ecological, and geopolitical consequences associated with the global water supply or how synthetic biology can help increase the supply of essential products, create new demand, and launch or upend entire industries, Thinking Big is designed to spark dialogue on important global issues that may impact today’s investors as well as future generations.

Fidelity’s Thinking Big initiative will continue to explore timely global themes throughout 2012, and will utilize digital video, social media, print and interactive Web elements, including a microsite for investors at and an additional site for financial advisors at

About Fidelity Investments
Fidelity Investments is one of the world’s largest providers of financial services, with assets under administration of $3.5 trillion, including managed assets of $1.6 trillion, as of May 31, 2012. Founded in 1946, the firm is a leading provider of investment management, retirement planning, portfolio guidance, brokerage, benefits outsourcing and many other financial products and services to more than 20 million individuals and institutions, as well as through 5,000 financial intermediary firms. For more information about Fidelity Investments, visit

Past performance is no guarantee of future results.

Keep in mind that investing involves risk. The value of your investment will fluctuate over time and you may gain or lose money.

Diversification does not ensure a profit or guarantee against loss. Investing involves risk, including risk of loss.

Because of their narrow focus, investments in one sector tend to be more volatile than investments that diversify across many sectors and companies.

Fidelity, Fidelity Investments, Turn Here, the Fidelity Investments, Pyramid Design logo, are a registered trademarks of FMR LLC.

Fidelity Brokerage Services LLC, Member NYSE, SIPC
900 Salem Street, Smithfield, RI 02917

Fidelity Investments Institutional Services Company, Inc.,
100 Salem Street, Smithfield, RI 02917

© 2012 FMR LLC. All rights reserved.